Efficacy and Safety of Weekly Paclitaxel With or Without Oral Alisertib in Patients With Metastatic Breast Cancer
Open Access
- 1 April 2021
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 4 (4) , e214103
Abstract
Breast cancer is a heterogeneous disease, with distinct subtypes defined by expression of hormone receptors and human epidermal growth factor receptor 2 (ERBB2, formerly HER2), as well as by gene expression profiles.1-3 Novel therapies that inhibit the function of other proteins that triple-negative (TN) and high-grade estrogen receptor (ER)–positive, ERBB2-negative breast cancer are dependent on are greatly needed.Keywords
This publication has 27 references indexed in Scilit:
- Aurora-A Identifies Early Recurrence and Poor Prognosis and Promises a Potential Therapeutic Target in Triple Negative Breast CancerPLOS ONE, 2013
- Expression of aurora kinase A is associated with metastasis-free survival in node-negative breast cancer patientsBMC Cancer, 2012
- Comprehensive molecular portraits of human breast tumoursNature, 2012
- Aurora kinase A outperforms Ki67 as a prognostic marker in ER-positive breast cancerBritish Journal of Cancer, 2012
- Relationship between Quantitative GRB7 RNA Expression and Recurrence after Adjuvant Anthracycline Chemotherapy in Triple-Negative Breast CancerClinical Cancer Research, 2011
- Gene-Expression Signatures in Breast CancerNew England Journal of Medicine, 2009
- Inhibition of P-Glycoprotein-Mediated Paclitaxel Resistance by Reversibly Linked Quinine HomodimersMolecular Pharmacology, 2009
- Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast CancerNew England Journal of Medicine, 2007
- MLN8054, a Small-Molecule Inhibitor of Aurora A, Causes Spindle Pole and Chromosome Congression Defects Leading to AneuploidyMolecular and Cellular Biology, 2007
- Drosophila Aurora A kinase is required to localize D-TACC to centrosomes and to regulate astral microtubulesJournal of Cell Biology, 2002